Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Safe, effective...

    Safe, effective DNA-based Zika vaccine developed

    Written by Ruby Khatun Khatun Published On 2017-10-07T10:58:33+05:30  |  Updated On 7 Oct 2017 10:58 AM IST
    Safe, effective DNA-based Zika vaccine developed

    Washington: A new generation DNA-based Zika vaccine has been found safe and effective at eliciting an immune response against the virus in early human clinical trials, scientists say.


    The GLS-5700 vaccine contains the synthetic DNA instructions for the host to learn how to mount an immune response against a specific Zika virus antigen.


    Zika virus is a mosquito-borne infection associated with birth defects and neurological complications in adults, said researchers from the University of Pennsylvania in the US.


    In 2015 and 2016, Zika virus spread rapidly through Brazil, the Caribbean, and the southern US. However, no approved vaccine or treatment is currently available.


    This is the first study to show that a DNA vaccine can produce an immune response against the virus with minimal adverse effects, opening the door to further trials to move this vaccine forward.


    "Synthetic DNA vaccines are an ideal approach for emerging infectious diseases like Zika," said David B Weiner, executive vice president of The Wistar Institute in the US.


    "This new generation of DNA vaccines can be designed and manufactured rapidly, they appear to be highly predictable for the generation of immunity in humans, have significant conceptual safety advantages," said Weiner, collaborating author on the study published in the New England Journal of Medicine.


    "They are more stable than most traditional vaccines, making them exceptionally practical to distribute during outbreaks, especially in regions where resources are limited and we need to be able to respond quickly to curb an emerging epidemic," he said.


    Researchers enrolled 40 participants in the safety trial between August and September last year. Two groups of 20 participants received two different doses of the vaccine candidate intradermally at zero, four, and 12 weeks.


    Each dosage was followed by Cellectra delivery at the site, which generates small, directional electric currents into the skin to facilitate optimal vaccine uptake, production of the intended antigen, and immune responses.


    Results showed that two weeks after the final dose 100 percent of study participants developed Zika-specific antibodies and 80 percent developed significant neutralizing antibodies against the virus.


    Importantly, serum from the study participants was able to protect immunocompromised mice from developing the disease after infection with Zika virus, indicating that the vaccine-induced antibodies can prevent infection in vivo (inside living tissues). The vaccine was also well tolerated.


    "Zika virus continues to be a threat to people living in the Americas and the Caribbean," said Pablo Tebas, a professor at the University of Pennsylvania and lead author on the study.


    "With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika," said Tebas.

    David B WeinerdevelopedDNA-based Zika vaccineeffectiveGLS-5700 vaccinehuman clinical trialsimmune responseNew England Journal of MedicinePablo TebasSafesynthetic DNA instructionsvaccinevirusZika vaccinezika virus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok